Gilead Sciences, Inc. (/ˈɡɪliəd/) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| GILD | GILEAD SCIENCES, INC. | 2025-12-02 09:27:14 | 125.95 | 1.62 | 1.3 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | 0000882095 | GILEAD SCIENCES, INC. | US3755581036 | 549300WTZWR07K8MNV44 | 943047598 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 333 LAKESIDE DR | FOSTER CITY | CA | 94404 | UNITED STATES | US | 6505743000 | 333 LAKESIDE DR, FOSTER CITY, CA, 94404 | 333 LAKESIDE DR, FOSTER CITY, CA, 94404 | GILEAD SCIENCES INC | Pharmaceutics | 1987-06-22 | Daniel O'Day | 17,600 | http://gilead.com | 60,000,000,000 | 1,242,000,000 | 1,240,679,623 | Gilead Sciences, Inc. (/ˈɡɪliəd/) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100. | 2025-11-27 14:36:38 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 60,000,000,000 | -7,000,000,000 | -10.4478 | 1,245,346,062 | -428,554 | -0.0344 |
| 2023 | 67,000,000,000 | 11,100,000,000 | 19.8569 | 1,245,774,616 | -1,330,538 | -0.1067 |
| 2022 | 55,900,000,000 | -6,700,000,000 | -10.7029 | 1,247,105,154 | -6,781,570 | -0.5408 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Johanna Mercier | Chief Commercial Officer | 2024 | 1,148,038 | 0 | 4,139,594 | 1,845,246 | 176,158 | 8,609,065 |
| Merdad V. Parsey | Chief Medical Officer | 2024 | 1,141,486 | 0 | 4,206,347 | 1,410,810 | 27,484 | 8,111,131 |
| Daniel P. O’Day | Chairman, Chief Executive Officer | 2024 | 1,771,201 | 0 | 12,426,816 | 4,028,096 | 1,338,268 | 23,689,392 |
| Andrew D. Dickinson | Chief Financial Officer | 2024 | 1,083,969 | 0 | 4,080,024 | 1,608,840 | 36,896 | 8,109,758 |
| Deborah H. Telman | Executive Vice President, General Counsel | 2024 | 967,723 | 0 | 2,151,425 | 1,436,148 | 704,083 | 6,071,879 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 17,600 |
| 2023 | 18,000 |
| 2022 | 17,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 28,754,000,000 | 27,116,000,000 | 27,281,000,000 |
| Cost Of Revenue | 6,251,000,000 | 6,498,000,000 | 5,657,000,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 5,907,000,000 | 5,718,000,000 | 4,977,000,000 |
| General And Administrative Expenses | 6,091,000,000 | 6,090,000,000 | 5,673,000,000 |
| Operating Expenses | 27,092,000,000 | 19,511,000,000 | 19,951,000,000 |
| Operating Income | 1,662,000,000 | 7,605,000,000 | 7,330,000,000 |
| Net Income | 480,000,000 | 5,665,000,000 | 4,592,000,000 |
| Earnings Per Share Basic | 0.38 | 4.54 | 3.66 |
| Earnings Per Share Diluted | 0.38 | 4.5 | 3.64 |
| Weighted Average Shares Outstanding Basic | 1,247,000,000 | 1,248,000,000 | 1,255,000,000 |
| Weighted Average Shares Outstanding Diluted | 1,255,000,000 | 1,258,000,000 | 1,262,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 9,991,000,000 | 6,085,000,000 | 5,412,000,000 |
| Marketable Securities Current | 0 | 1,179,000,000 | 973,000,000 |
| Accounts Receivable | 4,420,000,000 | 4,660,000,000 | 4,777,000,000 |
| Inventories | 1,710,000,000 | 1,787,000,000 | 1,507,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 19,173,000,000 | 16,085,000,000 | 14,443,000,000 |
| Marketable Securities Non Current | 0 | 1,163,000,000 | 1,245,000,000 |
| Property Plant And Equipment | 5,414,000,000 | 5,317,000,000 | 5,475,000,000 |
| Other Assets Non Current | 6,146,000,000 | 4,792,000,000 | 4,800,000,000 |
| Total Assets Non Current | 39,822,000,000 | 46,040,000,000 | 48,728,000,000 |
| Total Assets | 58,995,000,000 | 62,125,000,000 | 63,171,000,000 |
| Accounts Payable | 833,000,000 | 550,000,000 | 905,000,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 1,815,000,000 | 1,798,000,000 | 2,273,000,000 |
| Other Liabilities Current | 5,464,000,000 | 5,130,000,000 | 4,580,000,000 |
| Total Liabilities Current | 12,004,000,000 | 11,280,000,000 | 11,237,000,000 |
| Long Term Debt | 26,710,000,000 | 24,987,000,000 | 25,229,000,000 |
| Other Liabilities Non Current | 1,295,000,000 | 1,280,000,000 | 1,179,000,000 |
| Total Liabilities Non Current | — | — | — |
| Total Liabilities | — | — | — |
| Common Stock | 1,000,000 | 1,000,000 | 1,000,000 |
| Retained Earnings | 11,497,000,000 | 16,304,000,000 | 15,687,000,000 |
| Accumulated Other Comprehensive Income | 132,000,000 | 28,000,000 | 2,000,000 |
| Total Shareholders Equity | 19,330,000,000 | 22,833,000,000 | 21,240,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 2,386,000,000 | 2,339,000,000 | 1,780,000,000 |
| Share Based Compensation Expense | 835,000,000 | 766,000,000 | 637,000,000 |
| Other Non Cash Income Expense | -353,000,000 | -826,000,000 | -780,000,000 |
| Change In Accounts Receivable | -139,000,000 | -157,000,000 | 406,000,000 |
| Change In Inventories | 426,000,000 | 842,000,000 | 310,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 290,000,000 | -347,000,000 | 226,000,000 |
| Change In Other Liabilities | 108,000,000 | 458,000,000 | -775,000,000 |
| Cash From Operating Activities | 10,828,000,000 | 8,006,000,000 | 9,072,000,000 |
| Purchases Of Marketable Securities | 244,000,000 | 1,930,000,000 | 1,770,000,000 |
| Sales Of Marketable Securities | 2,265,000,000 | 510,000,000 | 412,000,000 |
| Acquisition Of Property Plant And Equipment | 523,000,000 | 585,000,000 | 728,000,000 |
| Acquisition Of Business | 4,840,000,000 | 1,152,000,000 | 1,797,000,000 |
| Other Investing Activities | -58,000,000 | 1,000,000 | 1,000,000 |
| Cash From Investing Activities | -3,449,000,000 | -2,265,000,000 | -2,466,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 3,918,000,000 | 3,809,000,000 | 3,725,000,000 |
| Issuance Of Common Stock | 422,000,000 | 232,000,000 | 309,000,000 |
| Repurchase Of Common Stock | 1,150,000,000 | 1,000,000,000 | 1,569,000,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | -281,000,000 | -279,000,000 | -173,000,000 |
| Cash From Financing Activities | -3,433,000,000 | -5,125,000,000 | -6,469,000,000 |
| Change In Cash | 3,906,000,000 | 673,000,000 | 74,000,000 |
| Cash At End Of Period | 9,991,000,000 | 6,085,000,000 | 5,412,000,000 |
| Income Taxes Paid | 2,779,000,000 | 3,990,000,000 | 3,136,000,000 |
| Interest Paid | 951,000,000 | 891,000,000 | 907,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 0.38 | 4.54 | 3.66 |
| Price To Earnings Ratio | 243.0789 | 17.8436 | 23.4563 |
| Earnings Growth Rate | -91.63 | 24.0437 | -26.2097 |
| Price Earnings To Growth Ratio | -2.6528 | 0.7421 | -0.8949 |
| Book Value Per Share | 37.6832 | 40.7412 | 41.3817 |
| Price To Book Ratio | 2.4512 | 1.9884 | 2.0746 |
| Ebitda | 6,622,000,000 | 12,938,000,000 | 10,443,000,000 |
| Enterprise Value | 133,719,390,000 | 121,800,480,000 | 129,831,750,000 |
| Dividend Yield | 0.034 | 0.0377 | 0.0346 |
| Dividend Payout Ratio | 8.1625 | 0.6724 | 0.8112 |
| Debt To Equity Ratio | 1.4757 | 1.1731 | 1.2948 |
| Capital Expenditures | 2,483,000,000 | 2,181,000,000 | 2,134,000,000 |
| Free Cash Flow | 8,345,000,000 | 5,825,000,000 | 6,938,000,000 |
| Return On Equity | 0.0248 | 0.2481 | 0.2162 |
| One Year Beta | 0.1703 | 0.5399 | 0.5059 |
| Three Year Beta | 0.4473 | 0.4836 | 0.4858 |
| Five Year Beta | 0.4659 | 0.5125 | 0.5716 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| O'Day Daniel Patrick | Director, Chairman & CEO | 2025-11-28 | 3,212 | D | 577,991 |
| O'Day Daniel Patrick | Director, Chairman & CEO | 2025-11-28 | 6,788 | D | 571,203 |
| Kramer Kelly A. | Director | 2025-11-28 | 2,805 | A | 4,144 |
| Kramer Kelly A. | Director | 2025-11-28 | 2,805 | D | 1,339 |
| Kramer Kelly A. | Director | 2025-11-28 | 2,805 | D | 0 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| John Boozman | Senator | 2025-05-14 | Sale (Full) | 2025-04-16 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2024-06-14 | Purchase | 2024-05-10 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2024-06-14 | Purchase | 2024-05-10 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2024-06-14 | Purchase | 2024-05-10 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2024-06-14 | Sale (Full) | 2024-05-08 | Joint | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Valerie Hoyle | 2025-10-10 | OR04 | Sale | 2025-09-23 | Spouse | $1,001 - $15,000 |
| Valerie Hoyle | 2025-09-12 | OR04 | Purchase | 2024-10-29 | Spouse | $1,001 - $15,000 |
| Jefferson Shreve | 2025-06-22 | IN06 | Sale | 2025-05-12 | — | $15,001 - $50,000 |
| Marjorie Taylor Greene | 2025-06-18 | GA14 | Purchase | 2025-06-06 | — | $1,001 - $15,000 |
| Josh Gottheimer | 2025-06-11 | NJ05 | Sale | 2025-05-14 | Joint | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Destination Wealth Management | 2025-09-30 | 387,638 | 3,492 | 111.0074 |
| Garden State Investment Advisory Services LLC | 2025-09-30 | 296,995 | 2,676 | 110.9847 |
| Voleon Capital Management LP | 2025-09-30 | 1,889,664 | 17,024 | 111 |
| Ausdal Financial Partners, Inc. | 2025-09-30 | 1,772,256 | 15,966 | 111.0019 |
| GREAT VALLEY ADVISOR GROUP, INC. | 2025-09-30 | 543,361 | 4,899 | 110.9126 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| iSHARES TRUST | 2025-09-30 | iShares Nasdaq Top 30 Stocks ETF | QTOP | 19,378 | 2,150,958 | 1.1089 |
| Investment Managers Series Trust II | 2025-09-30 | Class K | FORKX | 511 | 56,721 | 0.0694 |
| Investment Managers Series Trust II | 2025-09-30 | Class I | FORTX | 511 | 56,721 | 0.0694 |
| RYDEX SERIES FUNDS | 2025-09-30 | Class C | RYCFX | 39,678 | 4,404,258 | 4.8932 |
| RYDEX SERIES FUNDS | 2025-09-30 | Class A | RYBOX | 39,678 | 4,404,258 | 4.8932 |